@article{ajmcr2019722,
author={{Afzal, Muhammad Zubair and Shirai, Keisuke},
title={Complete Disappearance of Numerous Hepatic and Adrenal Metastases after One Dose of Pembrolizumab in a Patient with Metastatic Malignant Melanoma},
journal={American Journal of Medical Case Reports},
volume={7},
number={2},
pages={22--23},
year={2019},
url={http://pubs.sciepub.com/ajmcr/7/2/2},
issn={2374-216X},
abstract={Although pembrolizumab is the mainstay treatment in metastatic malignant melanoma and have shown a durable response. Heterogeneous or no response has been observed in 30-40% of the cases of metastatic malignant melanoma. Metastatic lung lesions are sensitive to checkpoint inhibitor therapy whereas liver and adrenal metastases show a variable response. We are reporting a case of malignant melanoma with numerous liver and adrenal metastases showing a significant and durable response to just a single dose of pembrolizumab.},
doi={10.12691/ajmcr-7-2-2}
publisher={Science and Education Publishing}
}